Coldstream Capital Management’s Genmab GMAB Stock Holding History

Coldstream Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,766	Closed	-$54.2K	–	1987
2025 Q1	$54.2K	Buy	+2,766	New	+$58K	﹤0.01%	1669

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Coldstream Capital Management's GMAB Position: Q2 2025 in Review

Coldstream Capital Management sold out of Genmab (GMAB) in Q2 2025, closing a stake of 2,766 shares — an estimated $54.2K sold.

Coldstream Capital Management first reported a position in GMAB in Q1 2025 and held it in 1 quarter. The position peaked at $54.2K in Q1 2025. 217 funds tracked by Wall St. Rank hold GMAB as of Q2 2025.

Coldstream Capital Management reported no remaining Genmab position as of Q2 2025 after selling out during the quarter.
Coldstream Capital Management sold 2,766 Genmab shares in Q2 2025, an estimated $54.2K.
Coldstream Capital Management first reported a position in Genmab in Q1 2025 and held it in 1 quarter.
Coldstream Capital Management's Genmab position peaked at $54.2K in Q1 2025.
217 funds tracked by Wall St. Rank held Genmab as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.